Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine

In previous trials, bevacizumab failed to prolong the overall survival time in newly diagnosed glioblastoma and at the first recurrence. Randomized clinical trials at the second or further recurrence following the failure of radiotherapy, temozolomide and lomustine, and retrospective analyses focusi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncol Lett
Autori principali: Wenger, Katharina J., Wagner, Marlies, You, Se-Jong, Franz, Kea, Harter, Patrick N., Burger, Michael C., Voss, Martin, Ronellenfitsch, Michael W., Fokas, Emmanouil, Steinbach, Joachim P., Bähr, Oliver
Natura: Artigo
Lingua:Inglês
Pubblicazione: D.A. Spandidos 2017
Soggetti:
Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5494648/
https://ncbi.nlm.nih.gov/pubmed/28693286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6251
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi